GLOBAL HEMP GROUP ANNOUNCES APPOINTMENT OF YOUSEF KAMHIYAH AS CHIEF FINANCIAL OFFICER
Vancouver, BC -- (January 11, 2024) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / FRANKFURT: GHG) is pleased to announce the appointment of Yousef Kamhiyah CPA, CBV, as Chief Financial Officer of the Company.
Mr. Kamhiyah is a Chartered Professional Accountant with a complementary Chartered Business Valuations license. He brings over 15 years of extensive Canadian experience in accounting, business valuation, tax, and business strategy. Demonstrating a highly technical proficiency with dual qualifications (CPA + CBV), Mr. Kamhiyah has successfully valued over 100 companies spanning diverse industries. His leadership extends to the real estate sector, where he has overseen finance and accounting teams, ensuring meticulous accuracy, timely execution, and adherence to mandates.
Prior to assuming his role as GHG’s CFO, Mr. Kamhiyah established Accuvalue in 2019, his boutique CPA CBV firm based in Montreal, Canada. His strategic management approach has been instrumental in contributing to the success of various companies he has worked with in the past. Prior to the formation of his independent accounting company, Yousef worked for a number of major accounting firms serving both public and private corporations in the areas of audit support, business and share valuations, and tax planning & compliance.
About Global Hemp Group Inc.
Global Hemp Group Inc. (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) is a dynamic company currently focused on two key business segments - Industrial Hemp and Biopharma.
The Industrial Hemp division’s primary focus lies in the environmental uses of hemp for construction and hemp for sustainable bio-energy sources, both contributing to a carbon-negative footprint. Our R&D team is engaged in developing Intellectual Property that can be patented and implemented within our projects and beyond. Prof. Víctor M. Castaño, Ph.D., a distinguished figure in applied science and nanotechnology leads the R&D Division for the organization.
The Health and Wellness Division is focused on the acquisition of exclusive patents and IP through licensing agreements. The Company acquired exclusive the rights to key patents and IP of Apollon Formularies plc., a UK-based international pharmaceutical company whose formulations and patents specialize in developing cancer treatments from natural biologics, including cannabinoids and functional mushrooms. More recently, the Company has signed a Letter of Intent with B-Organic R&D Corp. relating to the use of their Bioactive Lipid Agents (“BLA”) technology with cannabinoids, terpenes, flavonoids and mushroom extracts. BLA enhances the solubility and bioavailability of various “poorly soluble pharma ingredients”.
These strategic alliances form the basis for the commercialization of promising independently pre-clinically tested formulations, underscoring our commitment to cutting-edge innovation in the commercial biopharma sector.
For Further Information Contact Global Hemp Group
Investor Relations
Tel: 778-726-2900
info@globalhempgroup.com
https://www.globalhempgroup.com
Cautionary Note Regarding Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Global Hemp Group Inc., including, but not limited to the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, dependence upon regulatory approvals, the availability of future financing and exploration risk, the legality of cannabis and hemp. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Except as required by law, Global Hemp Group Inc. disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.